Neonatal immunization with pneumococcal conjugate vaccine in Papua New Guinea

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/303123

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

One million children die every year of pneumococcal (Pnc) disease, the majority in the third world. Many die in early infancy and babies may benefit from immunisation with a Pnc conjugate vaccine (PrevenarTM) at birth. The Papua New Guinea (PNG) Insatiate of Medical Research; Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia, will collaborate to closely examine the safety of this approach, particularly with regard to impact on the development of immunity and response to other vaccines given to infants. This study will also provide a unique opportunity for training of PNG and Australian scientists in both countries; transfer state-of-the-art immunological technology and stimulate further collaborations on respiratory infections in the region.

Funded Activity Details

Start Date: 01-01-2004

End Date: 01-01-2008

Funding Scheme: NHMRC Strategic Awards

Funding Amount: $1,181,966.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Infectious Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Infectious diseases | Neonatal | Pneumococcal vaccination | Respiratory diseases | Th1 / Th2 immune responses

Related Links